Efficacy of PD-1 Blockade in Refractory Microsatellite-Stable Colorectal Cancer With High Tumor Mutation Burden

Clin Colorectal Cancer. 2019 Dec;18(4):307-309. doi: 10.1016/j.clcc.2019.08.001. Epub 2019 Sep 4.

¹ Division of Medical Oncology, Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA.
² Enloe Hematology Oncology, Chico, CA.
³ Division of Hematology and Oncology, Department of Internal Medicine, UC Davis Comprehensive Cancer Center, Sacramento, CA.
⁴ Department of Medical Oncology, City of Hope National Medical Center, Duarte, CA.
⁵ Foundation Medicine Inc, Cambridge, MA.
⁶ Department of Radiation Oncology, UC Davis Medical Center, University of California, Sacramento, CA.
⁷ Division of Medical Oncology, Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA; The Angeles Clinic and Research Institute, Los Angeles, CA.
⁸ Division of Hematology and Oncology, Department of Internal Medicine, UC Davis Comprehensive Cancer Center, Sacramento, CA. Electronic address: [email protected].

No abstract available

Keywords: Checkpoint inhibitor; Metastatic colorectal cancer; Microsatellite stable; Mismatch repair proficient; Tumor mutational burden.

Publication types